It is a potential therapeutic target, as antibody inhibition can reduce tumor growth.[29] In COPD, MMP11-driven ECM changes may foster a pro-tumorigenic environment, linking it to increased lung cancer risk. The gene discussed is MMP11; the disease is lung carcinoma.